GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (OTCPK:BIOYF) » Definitions » Institutional Ownership

Biosyent (Biosyent) Institutional Ownership : 1.38% (As of Apr. 27, 2024)


View and export this data going back to . Start your Free Trial

What is Biosyent Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Biosyent's institutional ownership is 1.38%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Biosyent's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Biosyent's Float Percentage Of Total Shares Outstanding is 0.00%.


Biosyent Institutional Ownership Historical Data

The historical data trend for Biosyent's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosyent Institutional Ownership Chart

Biosyent Historical Data

The historical data trend for Biosyent can be seen below:

2023-05-31 2023-06-30 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31
Institutional Ownership 2.39 2.41 1.36 1.36 1.36 1.36 1.37 1.37 1.38 1.38

Biosyent Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Biosyent (Biosyent) Business Description

Traded in Other Exchanges
Address
2476 Argentia Road, Suite 402, Toronto, Mississauga, ON, CAN, L5N 6M1
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.

Biosyent (Biosyent) Headlines

From GuruFocus

BioSyent Announces Changes to Executive Management

By GlobeNewswire GlobeNewswire 09-10-2018

When Being Certain Isn't Enough

By Thomas Macpherson Thomas Macpherson 08-30-2019

BioSyent Announces Adoption of Restricted Share Unit Plan

By GlobeNewswire GlobeNewswire 03-06-2020

BioSyent Announces Grant of Restricted Share Units

By GlobeNewswire GlobeNewswire 03-31-2023

BioSyent Announces Approval of New Product

By GlobeNewswire GlobeNewswire 05-31-2023

BioSyent to Present at Upcoming Investor Conferences

By GlobeNewswire GlobeNewswire 04-25-2018

BioSyent to Present at The LD 500 Virtual Conference

By ACCESSWIRE ACCESSWIRE 08-25-2020

BioSyent Schedules Q2 and H1 2022 Earnings Release for August 23, 2022

By GlobeNewswire GlobeNewswire 08-17-2022